Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study

References

• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322–2333.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
   Google Scholar
• Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998; 58(18):4173–4179.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767–3775.
   PubMed Web of Science ®Google Scholar
• Magina KN, Pregartner G, Zebisch A, et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130(7):946–948.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Forsberg LA. Loss of chromosome Y (LOY) in blood cells is associated with increased risk for disease and mortality in aging men. Hum Genet.. 2017;136(5):657–663.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741–3750.
   PubMed Web of Science ®Google Scholar
• Krauth MT, Eder C, Alpermann T, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014;28(7):1449–1458.
   PubMed Web of Science ®Google Scholar
• Jung HA, Maeng CH, Park S, et al. Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia. Anticancer Res.. 2014;34(2):1037–1045.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. JCO. 2005;23(24):5705–5717.
   PubMed Web of Science ®Google Scholar
• Zhu CY, Yang H, Niu JH, et al. Clinical analysis of acute myeloid leukemia with t(8;21) (q22;q22) and loss of Y chromosome. Zhongguo shi yan xue ye xue za zhi. 2014; 22(4):950–956.
   PubMedGoogle Scholar
• Willatt L, Morgan SM. Shaffer LG, Slovak ML, Campbell LJ (2009): ISCN 2009 an international system for human cytogenetic nomenclature. Hum Genet. 2009;126(4):603–604.
   Google Scholar
• Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia. 2003;17(12):2318–2357.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013; 121(20):4056–4062.
   PubMed Web of Science ®Google Scholar
• Voso MT, Ottone T, Lavorgna S, et al. MRD in AML: the role of new techniques. Front Oncol. 2019;9:655.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Gong D, Li W, Hu LD, et al. Comparison of clinical efficacy of cytarabine with different regimens in postremission consolidation therapy for adult t(8;21) AML patients: a multicenter retrospective study in China. Acta Haematol. 2016;136(4):201–209.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642–4649.
   PubMed Web of Science ®Google Scholar
• Delgado J, Pereira A, Villamor N, et al. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014;99(9):1410–1420.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone marrow Transplant. 2013; 48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117(8):2366–2372.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331(14):896–903.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol.. 2006;135(2):165–173.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Bennett JM, Loffler H, et al. Acute myeloid leukemia with translocation (8;21). Leuk Lymphoma. 1996; 23(3–4):227–234.
   PubMed Web of Science ®Google Scholar
• Rege K, Swansbury GJ, Atra AA, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40(1–2):67–77.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Pasquini MC, Perez WS, et al. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transpl: J American Soc Blood Marrow Transpl. 2008;14(2):187–196.
   PubMed Web of Science ®Google Scholar
• Klein K, Kaspers G, Harrison CJ, et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2015;33(36):4247–4258.
   PubMed Web of Science ®Google Scholar
• Ustun C, Morgan E, Moodie EEM, et al. Core-binding factor acute myeloid leukemia with t(8;21): risk factors and a novel scoring system (I-CBFit). Cancer Med. 2018;7(9):4447–4455.
   PubMed Web of Science ®Google Scholar
• Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463–3468.
   PubMed Web of Science ®Google Scholar
• Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904–3911.
   PubMed Web of Science ®Google Scholar
• Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012; 120(14):2826–2835.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579–590.
   PubMed Web of Science ®Google Scholar